How many 6-K filings has Sanofi filed?

Sanofi (SNYNF) has 50 6-K (Foreign Current Report) filings on record, spanning Feb 2025 to Dec 2025.

What is a 6-K filing?

A 6-K is an SEC filing known as "Foreign Current Report." Current report filed by foreign private issuers for material events. Equivalent to the 8-K for domestic companies.

Where can I read Sanofi 6-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Sanofi 6-K filings, including risk assessment, sentiment analysis, and key financial figures.

Sanofi (SNYNF) — 6-K Filings

All 6-K filings from Sanofi. Browse 50 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (50)

Sanofi Updates Tolebrutinib Regulatory Submission — Dec 29, 2025 Risk: low
On December 24, 2025, Sanofi announced an update regarding its tolebrutinib regulatory submission for non-relapsing secondary progressive multiple sclerosis. Th
6-K Filing — Dec 23, 2025
Sanofi Agrees to Lower Drug Costs with US Government — Dec 22, 2025 Risk: medium
On December 19, 2025, Sanofi announced an agreement with the US government to reduce medicine costs. This agreement aims to balance lower prices with continued
6-K Filing — Dec 15, 2025
6-K Filing — Dec 12, 2025
Sanofi's Dupixent Gets EU Approval as First Targeted Medicine — Dec 3, 2025 Risk: low
On November 25, 2025, Sanofi announced that its drug Dupixent, developed with Regeneron, received approval in the European Union as the first targeted medicine
Sanofi's Dupixent Study Meets Endpoints — Nov 18, 2025 Risk: low
On November 7, 2025, Sanofi announced that the pivotal study for Dupixent, developed with Regeneron, met all primary and secondary endpoints. This filing is a F
6-K Filing — Nov 3, 2025
Sanofi's efdoralprin alfa shows positive results — Oct 31, 2025 Risk: low
On October 22, 2025, Sanofi announced positive results for its efdoralprin alfa drug. The drug met all primary and key secondary endpoints in a study for alpha-
Sanofi Prices $3 Billion Bond Issuance — Oct 28, 2025 Risk: low
On October 28, 2025, Sanofi announced the successful pricing of a USD 3 billion bond issuance. This filing is a Form 6-K report, indicating it's a report of a f
Sanofi Files 6-K with Mid-Year Financial Updates — Oct 27, 2025 Risk: low
Sanofi filed a 6-K on October 27, 2025, presenting unaudited condensed half-year consolidated financial statements as of June 30, 2025. These statements should
Sanofi Files 6-K, Updates EU Rezurock Review — Oct 24, 2025 Risk: low
On October 17, 2025, Sanofi announced an update regarding the regulatory review of Rezurock for chronic graft-vs-host disease (cGVHD) in the EU. The company als
Sanofi Files 6-K Report for October 2025 — Oct 24, 2025 Risk: low
On October 24, 2025, Sanofi filed a Form 6-K, reporting its activities for the month of October 2025. This filing includes a press release, Exhibit 99.1, which
Sanofi's AlphaMedixTM Drug Meets Phase 2 Efficacy Endpoints — Oct 15, 2025 Risk: low
On October 8, 2025, Sanofi announced that its AlphaMedixTM (212Pb-DOTAMTATE) drug successfully met all primary efficacy endpoints in a Phase 2 study. This devel
Sanofi Drug SAR446268 Gets FDA Fast Track Nod — Sep 26, 2025 Risk: low
On September 23, 2025, Sanofi announced that its investigational drug, SAR446268, received U.S. Food and Drug Administration (FDA) Fast Track designation for th
Sanofi's Dupixent Gets EU Green Light for Urticaria — Sep 22, 2025 Risk: low
On September 22, 2025, Sanofi announced that its drug Dupixent, developed with Regeneron, received a positive opinion from the European Medicines Agency's Commi
Sanofi's Tzield approved in China; Q3 sales rise 3.1% — Sep 17, 2025 Risk: low
On September 10, 2025, Sanofi announced that its drug Tzield received approval in China, marking it as the first disease-modifying therapy for adults with stage
Sanofi's amlitelimab succeeds in Phase 3 atopic dermatitis study — Sep 4, 2025 Risk: low
On September 4, 2025, Sanofi announced that its drug amlitelimab successfully met all primary and key secondary endpoints in the COAST 1 Phase 3 study for treat
Sanofi's Wayrilz Approved in US for Immune Thrombocytopenia — Sep 3, 2025 Risk: low
On August 29, 2025, Sanofi announced that its drug Wayrilz (tirabrutinib) received US approval as the first BTK inhibitor for immune thrombocytopenia (ITP). Thi
Sanofi's Rilzabrutinib Gets EU Orphan Designation — Aug 29, 2025 Risk: low
On August 14, 2025, Sanofi announced that its drug rilzabrutinib received Orphan Drug Designation from the European Union for the treatment of IgG4-related dise
Sanofi Completes Vigil Neuroscience Acquisition — Aug 7, 2025 Risk: low
On August 6, 2025, Sanofi announced the completion of its acquisition of Vigil Neuroscience, Inc. The filing incorporates a press release detailing this signifi
Sanofi's Sarclisa Gets EU Approval for Multiple Myeloma — Jul 31, 2025 Risk: low
On July 25, 2025, Sanofi announced that its drug Sarclisa received EU approval for treating transplant-eligible newly diagnosed multiple myeloma. This marks a s
Sanofi Files 6-K Report for July 2025 — Jul 31, 2025 Risk: low
On July 31, 2025, Sanofi filed a Form 6-K, reporting on events for the month of July 2025. The filing incorporates by reference a press release issued by the co
Sanofi's SAR446597 Gets FDA Fast Track for Geographic Atrophy — Jul 22, 2025 Risk: low
On July 16, 2025, Sanofi announced that its investigational drug, SAR446597, received Fast Track designation from the U.S. Food and Drug Administration (FDA) fo
Sanofi Files 6-K Report — Jul 18, 2025 Risk: low
On July 18, 2025, Sanofi filed a Form 6-K with the SEC, reporting information as of the same date. The filing indicates Sanofi's principal executive offices are
Sanofi's Riliprubart Gets US Orphan Drug Nod — Jul 2, 2025 Risk: low
On June 25, 2025, Sanofi announced that its investigational antibody, riliprubart, received Orphan Drug Designation from the U.S. Food and Drug Administration (
Sanofi's Dupixent Outperforms Xolair in CRS Study — Jun 24, 2025 Risk: low
On June 15, 2025, Sanofi announced that its drug Dupixent showed superiority over Xolair (omalizumab) in treating chronic rhinosinusitis with nasal polyps (CRSw
Sanofi Prices €1.5 Billion Bond Issue — Jun 18, 2025 Risk: low
On June 17, 2025, Sanofi announced the successful pricing of a €1.5 billion bond issuance. This financial move is part of the company's ongoing funding strategy
Sanofi Ramps Up Beyfortus Shipments Ahead of RSV Season — Jun 17, 2025 Risk: low
On June 9, 2025, Sanofi announced the acceleration of global shipping for its Beyfortus (nirsevimab-afm) product. This initiative aims to ensure healthcare prov
Sanofi's Rilzabrutinib gets US Orphan Drug status for sickle cell — Jun 6, 2025 Risk: low
On June 3, 2025, Sanofi announced that its drug Rilzabrutinib received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatmen
Sanofi and Blueprint Medicines Announce Collaboration — Jun 2, 2025 Risk: low
On June 2, 2025, Sanofi announced a joint press release with Blueprint Medicines Corporation. This filing incorporates the press release as Exhibit 99.1, detail
Sanofi Completes DR-0201 Acquisition, Updates on Beyfortus — May 30, 2025 Risk: low
On May 27, 2025, Sanofi announced the completion of its acquisition of DR-0201. Additionally, on May 29, 2025, Sanofi provided an update on its product Beyfortu
Sanofi to Acquire Vigil Neuroscience for $1.4B — May 22, 2025 Risk: medium
On May 22, 2025, Sanofi announced its intention to acquire Vigil Neuroscience, Inc. for an aggregate value of $1.4 billion. This acquisition aims to bolster San
Sanofi Files 6-K on April 30th Annual Meeting — May 5, 2025 Risk: low
Sanofi filed a Form 6-K on May 5, 2025, reporting on its Annual General Meeting held on April 30, 2025. The filing includes a press release from April 30, 2025,
Sanofi Closes Opella Deal, Creates Consumer Health Leader — Apr 30, 2025 Risk: low
On April 30, 2025, Sanofi announced the closing of its transaction with CD&R for Opella, its global consumer healthcare business. This strategic move aims to es
Sanofi Files 6-K Report for April 2025 — Apr 24, 2025 Risk: low
On April 24, 2025, Sanofi filed a Form 6-K, reporting on events for the month of April 2025. This filing includes a press release, attached as Exhibit 99.1, whi
Sanofi's Dupixent Approved for Chronic Spontaneous Urticaria in US — Apr 22, 2025 Risk: low
On April 18, 2025, Sanofi announced that its drug Dupixent received US FDA approval as a new targeted therapy for chronic spontaneous urticaria (CSU). This mark
Sanofi Respiratory Pipeline Advances with New Asthma Data, COPD Studies Planned — Apr 16, 2025 Risk: low
On April 15, 2025, Sanofi announced advancements in its respiratory pipeline, presenting new data for asthma treatments and outlining plans for new clinical stu
Sanofi's Tolebrutinib Shows MS Disability Benefit in Phase 3 — Apr 10, 2025 Risk: low
Sanofi announced on April 8, 2025, that Phase 3 data for its drug tolebrutinib, published in the New England Journal of Medicine (NEJM), demonstrated a benefit
Sanofi's Rilzabrutinib Gets Orphan Drug Status for Rare Diseases — Apr 4, 2025 Risk: low
On April 3, 2025, Sanofi announced that its investigational drug, Rilzabrutinib, received Orphan Drug Designation from the U.S. Food and Drug Administration (FD
Sanofi's Dupixent Approved in Japan for COPD — Apr 2, 2025 Risk: low
On March 28, 2025, Sanofi announced that Dupixent received approval in Japan as the first biologic medicine for patients suffering from Chronic Obstructive Pulm
Sanofi's Tolebrutinib Gets FDA Priority Review for MS — Mar 26, 2025 Risk: medium
On March 25, 2025, Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental New Drug Application (sND
Sanofi to Acquire Dren Bio to Boost Immunology Pipeline — Mar 20, 2025 Risk: low
On March 20, 2025, Sanofi announced its intention to acquire Dren Bio, Inc. for an undisclosed amount. This acquisition aims to bolster Sanofi's immunology pipe
Sanofi's Dupixent Shows Promise in Bullous Pemphigoid Trial — Mar 10, 2025 Risk: low
On March 8, 2025, Sanofi announced positive pivotal data for Dupixent in treating bullous pemphigoid, presented at the American Academy of Dermatology (AAD) ann
Sanofi Prices EUR 1.5 Billion Bond Issue — Mar 6, 2025 Risk: low
On March 5, 2025, Sanofi announced the successful pricing of a EUR 1.5 billion bond issue. This filing is a Form 6-K report for the month of March 2025, indicat
Sanofi Presents New Duvakitug Data at ECCO 2025 — Feb 28, 2025 Risk: low
On February 22, 2025, Sanofi announced new data for its drug duvakitug at the ECCO 2025 conference. The data presented reinforce the drug's potential as a best-
Sanofi's Dupixent Gets FDA Priority Review for Bullous Pemphigoid — Feb 20, 2025 Risk: low
On February 18, 2025, Sanofi announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Applicatio
Sanofi ExPEC Vaccine Phase 3 Study Update — Feb 13, 2025 Risk: low
On February 13, 2025, Sanofi announced an update regarding its Phase 3 clinical study for an extraintestinal pathogenic E. coli (ExPEC) vaccine. The company rep
Sanofi Files 6-K Reporting Press Release Publication — Feb 7, 2025 Risk: low
In February 2025, Sanofi filed a Form 6-K to report the publication of a press release, attached as Exhibit 99.1. This filing is for the month of February 2025
Sanofi's Sarclisa Gets EU Approval for Multiple Myeloma — Feb 3, 2025 Risk: low
On January 31, 2025, Sanofi announced that its drug Sarclisa, in combination with standard therapy, became the first anti-CD38 treatment approved in the EU for

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX